Dechra Pharmaceuticals PLC Logo

Dechra Pharmaceuticals PLC

Develops & sells veterinary pharmaceuticals for companion animals, exclusively to veterinarians.

DPH | IL

Overview

Corporate Details

ISIN(s):
US2434351043
LEI:
213800J4UVB5OWG8VX82
Country:
United Kingdom
Address:
24 CHESHIRE AVENUE, CW9 7UA NORTHWICH
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dechra Pharmaceuticals PLC is a global specialist in veterinary pharmaceuticals and related products. The company focuses on the development, manufacture, marketing, and sales of high-quality products designed to improve animal health and welfare. Its portfolio includes a range of drugs and therapies for the prevention, diagnosis, and treatment of conditions in animals, with a focus on companion animals like dogs, cats, and horses. Dechra markets its products exclusively to veterinarians worldwide, positioning itself as a dedicated partner to the profession. The company also provides educational support through resources like the Dechra Academy to help veterinary professionals stay current with industry advancements.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-01-23 17:41
Major Shareholding Notification
Holding(s) in Company
English 23.4 KB
2024-01-18 16:14
Major Shareholding Notification
Holding(s) in Company
English 21.7 KB
2024-01-18 11:11
Major Shareholding Notification
Holding(s) in Company
English 26.8 KB
2024-01-17 15:01
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB
2024-01-17 13:01
Delisting Announcement
Holding(s) in Company
English 51.4 KB
2024-01-17 13:00
Major Shareholding Notification
Holding(s) in Company
English 54.9 KB
2024-01-17 12:16
Major Shareholding Notification
Holding(s) in Company
English 29.1 KB
2024-01-17 09:15
Delisting Announcement
Cancellation of listing and admission to trading
English 24.9 KB
2024-01-17 08:30
Major Shareholding Notification
Holding(s) in Company
English 21.6 KB
2024-01-16 17:54
Major Shareholding Notification
Holding(s) in Company
English 22.5 KB
2024-01-16 16:25
Major Shareholding Notification
Form 8.3 - Dechra Pharmaceuticals plc
English 46.1 KB
2024-01-16 15:43
Major Shareholding Notification
Holding(s) in Company
English 31.2 KB
2024-01-16 13:04
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB
2024-01-16 11:15
AGM Information
Scheme of Arrangement becomes Effective
English 45.8 KB
2024-01-16 10:00
Major Shareholding Notification
Holding(s) in Company
English 29.7 KB

Automate Your Workflow. Get a real-time feed of all Dechra Pharmaceuticals PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dechra Pharmaceuticals PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Dechra Pharmaceuticals PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
Celltrion Pharm Inc. Logo
South Korea
068760
Develops bone grafts, artificial joints, and enzymes for the biopharmaceutical sector.
South Korea
049180
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN
Celularity Inc Logo
Develops off-the-shelf cell therapies from placentas for cancer and aging-related diseases.
United States of America
CELU
Centessa Pharmaceuticals plc Logo
Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.
United States of America
CNTA
Century Therapeutics, Inc. Logo
Developing iPSC-derived, off-the-shelf cell therapies for cancer & autoimmune diseases.
United States of America
IPSC
Cereno Scientific AB Logo
Develops epigenetic therapies for rare cardiovascular and pulmonary diseases.
Sweden
CRNO
CERO THERAPEUTICS HOLDINGS, INC. Logo
Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.
United States of America
CERO
CERUS CORP Logo
Develops pathogen reduction technology to safeguard the global blood supply for healthcare providers.
United States of America
CERS

Talk to a Data Expert

Have a question? We'll get back to you promptly.